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Pulmonary surfactant spreads to the hydrated air–lung interface and reduces the surface tension to a very small value. This function fails in
acute respiratory distress syndrome (ARDS) and the surface tension stays high. Dysfunction has been attributed to competition for the air–lung
interface between plasma proteins and surfactant or, alternatively, to ARDS-specific alterations of the molecular profile of surfactant. Here, we
compared the two mechanisms in vitro, to assess their potential role in causing respiratory distress. Albumin and fibrinogen exposure at or above
blood level concentrations served as the models for testing competitive adsorption. An elevated level of cholesterol was chosen as a known
adverse change in the molecular profile of surfactant in ARDS. Bovine lipid extract surfactant (BLES) was spread from a small bolus of a
concentrated suspension (27 mg/ml) to the air–water interface in a captive bubble surfactometer (CBS) and the bubble volume was cyclically
reduced and increased to assess surface activity of the spread material. Concentrations of inhibitors and the concentration and spreading method of
pulmonary surfactant were chosen in an attempt to reproduce the exposure of surfactant to inhibitors in the lung. Under these conditions, neither
serum albumin nor fibrinogen was persistently inhibitory and normal near-zero minimum surface tension values were obtained after a small
number of cycles. In contrast, inhibition by an increased level of cholesterol persisted even after extensive cycling. These results suggest that in
ARDS, competitive adsorption may not sufficiently explain high surface tension, and that disruption of the surfactant film needs to be given causal
consideration.
© 2007 Elsevier B.V. All rights reserved.Keywords: Captive bubble surfactometer (CBS); Pulmonary surfactant; Fibrinogen; Serum albumin; Cholesterol; Polyethylene glycol (PEG); Bovine lipid extract
surfactant (BLES)1. Introduction
Pulmonary surfactant consists of about 40% w/w of the
saturated phospholipid dipalmitoylphosphatidylcholine (DPPC)
as well as unsaturated phospholipids, cholesterol (5–10% w/w)
and surfactant associated proteins. It is secreted by the alveolar
type II epithelial cells as lamellar bodies into the aqueous lining
that covers the epithelium to the air [1–4]. Lamellar bodies
expand into tubular myelin [5] which spreads to form a tightly
packed molecular film at the lung's interface to the air [6–10].
The film counteracts the otherwise high surface tension (γ) of
the interface (about 70 mN/m for a free air–water interface) and
reduces it almost to 0 mN/m at residual lung capacity [11] when
the film is most tightly packed. During inhalation γ rises as the
lung expands, but stays below 10 mN/m during tidal breathing⁎ Corresponding author. Tel.: +1 403 210 8177; fax: +1 403 270 8928.
E-mail address: mamrein@ucalgary.ca (M.W. Amrein).
0005-2736/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2007.10.027[12]. Low surface tension is needed for ease of breathing and to
reduce the Laplace pressure preventing collapse of the alveoli.
The area reduction associated with reaching near-zero surface
tension during exhalation is minimal, indicating that in the
healthy lung the compressibility of the surfactant film is very
small [12]. Note that to our knowledge, absolute values of film
compressibility in the lung have not been published to date.
This is likely because the effective change in the interface
during breathing cannot be directly measured and so compres-
sibility is not readily obtainable.
Acute respiratory distress syndrome (ARDS) is a common
and devastating spectrum of disease that has a high overall
mortality rate. The published, population-based incidence
of ARDS ranges from 1.5 to 5.3/105 population/year and a
mortality rate of 36% to 60% [13]. The strongest clinical
evidence of a cause–effect relationship was identified for sepsis,
aspiration, trauma, and multiple transfusions [13]. A central
component of this condition is pulmonary surfactant inhibition
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inflammation gives rise to lipases and proteases, radical oxygen
species (ROS) and other inflammatory mediators within lung
tissue. Damage to the alveolar wall allows these compounds,
together with blood–serum components, access to the alveolar
space where they can impair pulmonary surfactant. Since
surfactant impairment is a major factor in the morbidity and
mortality of ARDS, it has been targeted by replacement
surfactant therapy. However, success has been minimal (for a
review, see [14]). This is likely because the exogenous surfactant
also becomes inactivated in the affected lung. It is now generally
believed that successful treatment will depend on an in-depth
understanding of the impairment mechanisms.
Current understanding of surfactant inhibition has suggested
two alternative mechanisms, one being competition for the
interface [14–17]. According to this model, blood proteins,
inflammation specific proteins or other surface active sub-
stances adsorb to the air–water interface and compete with the
pulmonary surfactant for the interface. A high surface tension
will then result from an absence of surfactant film over sig-
nificant portions of this interface. The other model of surfactant
inhibition attributes high surface tension to impairment of the
surfactant film itself [18–24]. Small amphiphilic molecules
such as free fatty acids, cholesterol and lysolipids are thought to
associate with the surfactant film and render it dysfunctional
[18–20]. The detrimental effect of surfactant lipid and protein
oxidation by ROS also falls into this category of surfactant
impairment [21–24].
In the current study, we compared the two alternative mech-
anisms of surfactant inhibition, competition for the interface
versus impairment of the surfactant film itself in vitro under
conditions which attempt to more adequately reflect those in the
lung than the conditions chosen in earlier studies (see
“Discussion”). The captive bubble surfactometer (CBS) was
used for measuring the surface activity, because it comes clos-
est to mimicking lung function as determined in vivo from
pressure–volume studies [25]. The CBS consists of a chamber,
filled with buffer, with an air bubble floating against a convex
agarose ceiling. Varying the volume in the chamber alters
bubble size changing the surface tension. Alterations in γ at the
air–liquid interface in the CBS are seen as a flattening of the
bubble as γ falls and a rounding as it rises [26]. We investigated
films formed from clinically used bovine lipid extract surfactant
(BLES) [27]. BLES contains all lipids of natural surfactant with
the exception of cholesterol. We used BLES as is to reflect
normal surfactant and after the addition of 20% w/w cholesterol
to model the elevated amount found in diseased lungs [28,29].
We have found that this level of cholesterol, while not being the
only neutral lipid change in diseased lung, produces marked
inhibition of surfactant while lower physiological levels do not
[19]. BLES also contains the two highly hydrophobic surfactant
associated proteins SP-B and SP-C in natural proportions. To
study the effect of serum proteins, we added either serum
albumin or fibrinogen to the aqueous phase. The protein con-
centrations (40 mg/ml for albumin, 3 mg/ml for fibrinogen)
were chosen to reflect what the alveolus might be exposed to
in extreme ARDS. Albumin was also tested at 80 mg/ml. Theprotein was added either before or after a BLES film had been
formed at the bubble air–water interface to assess the competing
hypotheses. Surfactants were administered to the air–water
interface in a small but concentrated (27 mg/ml phospholipids)
aqueous bolus of surfactant [19,30]. We then observed the
change in γ to see how serum proteins affected film formation.
Next the bubble size was rapidly increased in size and changes
in γ were followed to monitor the films' ability to incorporate
additional material and then accommodate this addition.
Thereafter the bubble size was slowly decreased and increased
(quasi-static cycles), followed by rapid cycles (dynamic cycles).
A similar experimental protocol was pursued with BLES con-
taining 20% w/w cholesterol. Finally, we also explored whether
the addition of PEG to the aqueous phase reversed the inhibition
by cholesterol or albumin similar to the published findings for
serum protein inhibition.
2. Materials and methods
2.1. Surface activity assessment
The surface activity of the surfactant was determined using a laboratory-
built, fully computer controlled CBS evolved from the apparatus described
earlier [7]. The chamber of the CBS was filled with a buffer solution (140 mM
NaCl, 10 mM Hepes, and 2.5 mM CaCl, pH 6.9), with or without protein, as
described below and a small (0.035–0.040 ml) bubble was allowed to float up to
the chamber's concave agarose ceiling. Then, ∼0.05 μl of the surfactant was
deposited at the air–buffer interface by means of a transparent capillary. This
allowed a precisely defined volume of surfactant to be deposited under visual
control. The bubble was imaged by a video camera (Pulnix TM 7 CN) and
recorded for later analysis. The chamber was kept at 37 °C during the
experiment. A 5 min adsorption (film formation) period followed the
introduction of the surfactant into the chamber during which the bubble was
not manipulated and the change in γ was monitored. The chamber was then
sealed and the bubble was rapidly (1 s) expanded to a volume of 0.13 ml. Five
min after the bubble was expanded quasi-static cycling commenced. In the
quasi-static portion of the experiment the bubble size was first reduced and then
enlarged in a stepwise fashion by altering the internal volume of the chamber.
Each step had two components; a 3 s change in volume followed by a 4 s delay
when the chamber volume remained unchanged allowing the film to “relax”.
There was a 1 min inter-cycle delay between each of four quasi-static cycles and
a further 1 min delay between the quasi-static and dynamic cycles. In the
dynamic cycle portion of the experiment, the bubble volume was smoothly
varied over the same range as the last quasi-static cycle for 20 cycles at a rate of
20 cycles/min. Bubble volume, interfacial area, and γ were calculated using
height and diameter of the bubble as described [31].
2.2. Surfactant
BLES (a kind gift from the manufacturer BLES Biochemicals Inc, London
Ontario see Yu et al. [27] for analysis of BLES composition) in non-buffered
normal saline (pH 5–6) with calcium added and at a phospholipid concentration
of 27 mg/ml was used as is for the protein-inhibition experiments or after the
addition of cholesterol (Sigma Chemicals, St. Louis, MO) for the cholesterol-
inhibition experiments. Cholesterol cannot be added reliably and quantitatively
to BLES while in aqueous suspension. Therefore, BLES was first taken up in
organic solvent, cholesterol added and the mixture returned into an aqueous
solution as follows. A 1:1:1 ratio solution of methanol, chloroform, and BLES
by volume was first vortexed and then spun at 100 g for 5 min. The chloroform
phase contained most of the BLES and was saved. For complete recovery of
BLES, the water/methanol phase was extracted a second time with chloroform
and the two fractions of BLES in chloroform pooled. To this pool, cholesterol in
chloroform was added to a final concentration of 20% w/w with respect to BLES
phospholipids. The solution was dried under N2 and re-suspended in buffer
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aqueous suspension of BLES and cholesterol at a phospholipid concentration of
27 mg/ml.
2.3. The aqueous phase of the CBS
Sucrose, 10% w/w, was added to the buffer to increase its density so that the
surfactant suspension would float to make and remain in contact with the bubble
upon injection (see below). Adding sucrose does not affect surface activity of
surfactant [19]. For the protein-inhibition experiments, proteins were added to
the buffer either before, or after the surfactant was placed at the air–buffer
interface of the CBS. The proteins remained present throughout all tests. Dry
powders of bovine serum albumin (catalogue-number: A7906) and fibrinogen
from human plasma (catalogue-number F4883) were purchased from Sigma-
Aldrich. Dry serum albumin was dissolved in buffer to a final concentration of
40 mg/ml or 80 mg/ml and fibrinogen to a concentration of 3 mg/ml. In two
instances, polyethylene glycol (PEG) was introduced into the chamber, after the
surfactant had been injected. PEG (MW 6000, Fluka Chemicals Co., Switzer-
land) was dissolved in buffer and injected into the sample chamber to a final
concentration of 25 mg/ml.
2.4. Representation of CBS results
Film formation was plotted as surface tension γ versus time. For quasi-static
and dynamic cycles, surface tension (γ)–bubble area (A) isotherms were plotted
and the film's two-dimensional compressibility (β) was also calculated,
according to the following equation, to further describe the surfactant films'
surface activity
b ¼ 1=Að Þ  DA=Dgð Þ:
In this equation A is the absolute bubble area at a given surface tension γ,
and values for β at γ =10 mN/m (βγ10) are given in the results.
2.5. Statistical analysis of CBS experiments
Nonparametric tests (SPSS 14.0) of differences in surface tension during
film formation and in minimum surface tension attained in bubble cycling were
performed with Pb0.05 used as the standard for significance in all cases. The
Freidman test for multiple related measures was used first to test for main within
treatment effects and the Wilcoxon paired related measures test was used for
subsequent orthogonal comparisons after overall significance was determined.
The Kruskal–Wallis and the Mann–Whitney U tests for independent samples
were similarly used to determine overall between treatment effects and to make
subsequent specific orthogonal comparisons.
2.6. Electron microscopy
Five μl each of an aqueous suspension of either BLES of 27 mg/ml, BLES at
5 mg/ml, or BLES at 5 mg/ml plus PEG were put down onto a bare electron
microscopy grid, excess of the suspension removed by filter paper and the grid
injected into liquid ethane. Grids were transferred onto a cryo-holder and imaged
in a Tecnai F-20 (FEI) at −100 °C without further staining.3. Results
3.1. Film formation
Film formation was studied in two ways. As the first step in
the experimental protocol, we injected the aqueous suspension
of BLES close to the bubble from a transparent capillary
(Fig. 1a). The surfactant then made contact with the bubble
surface and the resultant drop in γ was observed over 5 min
(Fig. 1b). The drop in surface tension after injection of sur-factant as a function of time was indicative of the ability of
surfactant to form a functional film at a clean or serum protein-
covered interface. In the following sections, results are shown
for adsorption of BLES onto a serum protein-free buffer and a
buffer containing either serum albumin or fibrinogen. Finally,
adsorption of BLES with 20% w/w cholesterol onto a serum-
free buffer is described. Results on the adsorption of the films
for all conditions are summarized in Table 1.
For all samples, upon making contact, the surfactant spread
over the entire bubble and lowered the surface tension.
However, the time course of film formation differed signifi-
cantly for different treatments (Fig. 1b). Spreading BLES onto a
protein-free buffer resulted in a drop of γ to between 35.0 and
30.0 mN/m within 0.15 s for all but three samples. Thereafter,
γ dropped further to reach a value of 23.5 (±0.05) mN/m within
30 s (e.g. Fig. 1b, black curve). The equilibrium surface tension
obtained with BLES is ∼23.5 mN/m (e.g. [19]). Reaching this
surface tension indicates that the process of film formation is
complete. Hence, film formation could be seen as two processes
with an initial extremely fast drop in γ reflecting surfactant
material spreading from the point of contact to cover the
interface. The following slower further drop in γ to equilibrium
may reflect alterations in the surfactant film architecture after
the surface has been covered.
Spreading BLES onto a serum protein containing buffer was
chosen to test for the effect of competitive adsorption, by first
giving the protein time to adsorb to the interface before injecting
surfactant. The initial drop in surface tension was significantly
slower under this condition. With serum albumin at the inter-
face, the initial drop in γ to below 35.0 mN/m took longer than
0.15 s irrespective of whether the protein concentration was 40
or 80 mg/ml in the buffer. The results were more varied when
the buffer contained fibrinogen. Here one sample dropped
below 35.0 mN/m in less than 0.15 s and one took over 7 s to
pass this threshold. Despite this initially slower surfactant
adsorption, the time for these samples to reach equilibrium was
not significantly different from those without protein in the
buffer. Hence, surface coverage by surfactant appeared to have
been slowed down by the presence of serum proteins, but after
an initial coverage, film refinement progressed rapidly enough
to obscure the effect by the time equilibrium was reached. Initial
film formation was also statistically significantly slower when
cholesterol was added to the surfactant, and surface tension took
longer than 0.15 s to drop below the 35.0 mN/m criterion in all
but one case. This slower initial spreading did not significantly
affect the ability to reach equilibrium within 30 s with only one
case failing to reach this criterion. The remaining sample then
asymptotically approached equilibrium over the allotted 5 min
(Fig. 1b, grey curve).
Next, the bubble was rapidly expanded to approximately
double the size of the air–water interface and γ observed for
another 5 min. Surfactant not only forms a single layer but
spreads to the interface with patches of multiple surface asso-
ciated layers when prepared as in the current study [19,32].
Adsorption of additional surfactant from this surface associated
reservoir to the interface was thus observed upon rapid expan-
sion. For films devoid of cholesterol the surface tension peaked
Fig. 1. Adsorption of surfactant. (a) (1) An air bubble in buffer floats against the agar ceiling of the captive bubble surfactometer chamber (image width 6 mm). (2) A
transparent capillary is advanced just to the air–water interface from below and a small amount of surfactant ejected (BLES, 27 mg/ml). This material contacts the
bubble surface causing it to flatten (3). Due to interlacing of the video image, the old shape of the bubble is evident in frame 3 field 1 as fine horizontal stripes, whereas
the new shape appears solid in the second field of this frame. The time display at the top left of each image indicates a time change of 0.1 s between image frames 3 and
4. This change in shape brings the bubble out of contact from the capillary (4). (b) Two plots of the surface tension over time as calculated from video frames such as
shown in (a). The inset represents the initial part of the curve at higher time resolution. The dark curve is an example of BLES being adsorbed to the air–water interface
of a bubble in buffer, in the absence of a potential inhibitor. Note the very rapid initial film formation. The plot in grey shows the adsorption of BLES containing 20%
w/w cholesterol. Initial film formation is slightly slower under this condition.
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absence of serum proteins while films containing 20% w/w
cholesterol reached significantly higher surface tensions.
Hence, insertion of new material from the surface associated
reservoir was less efficient for films containing excess choles-
terol than for films without cholesterol. However, by 60 s after
expansion completed, all films had returned to equilibrium with
only one surface tension value remaining above 24.0 mN/m. In
our experimental protocol, rapid expansion followed by a 5 min
waiting period concluded the assessment of film formation.3.2. Film expansion and compression
After film formation, the bubble volume first was slowly
stepwise decreased and increased (quasi-static cycles). Quasi-
static cycles reveal whether a surfactant film is able to sustain a
low surface tension over time. This is an important parameter of
surfactant function. A large proportion of the lung is experiencing
minimal or no area change during tidal breathing and these parts
of the lung too require stable near-zero surface tension tomaintain
the alveolar structure. The volumewas then cycled dynamically to
Table 1
Summary of results
The column headed “film spreadb0.15 s” indicates for each condition the percentage from all individual tests where the surface tension γ fell below 35 mN/m within
0.15 s. This criterion is indicative of whether film formation was slowed by the presence of inhibitors or not. The second column shows the percentages of films that
reached very low surface tension (γminb2 mN/m) for the first compression after film formation (i.e. the first compression of the first quasi-static compression–
expansion cycles), and the following columns show the first series of dynamic cycles, the second, and the third of quasi-static cycles respectively. Another measure of
function, the median compressibility at a surface tension of 10 mN/m (median βγ10 [m/N] shown in the second column of each set) indicates whether a film was
sufficiently incompressible. In the lung, a low compressibility of the surfactant film is found, as the very low surface tension required at end expiration occurs with a
small area change. In the table, “–” denotes incidences where a surface tension of 10 mN/m was not achieved, and, hence, compressibility not measured. Cells with a
grey background denote significantly impaired function.
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Quasi-static and dynamic cycles were repeated to see whether
impaired surfactant regained function or functional surfactant
became impaired upon further cycling. All results on film
expansion and compression are summarized in Table 1.
Fig. 2 shows the compression component of the isotherms
for BLES, spread on buffer containing no protein (control,
upper row), 80 mg/ml albumin (middle row) or 3 mg/ml
fibrinogen (lower row). The individual compression curves for
the repeats under each condition are denoted by different shades
of grey. The main results are also summarized in Table 1.
During the first compression, all films exposed to protein were
at least partially dysfunctional in that the surface tension
dropped less rapidly than control during size reduction. At
γ=10 mN/m, median compressibility was 20 m/N as compared
to 11 m/N for the control. Note that at γ =10 mN/m a com-
pressibility on the order of 10 m/N is consistent with molecules
becoming more tightly packed at the interface. Much larger
values indicate that some film collapse occurs and molecules are
removed from the interface. Some films reached a surface
tension near zero (γminb2mN/m), others did not. Interestingly,
there was not a tight association between compressibility and
low γmin during the first compression of the films.However, inhibition was not persistent for all films formed
with protein present in the buffer during further cycling. All
signs of inhibition had virtually disappeared by the forth quasi-
static cycle (median βγ10 6–7 m/N, similar to control). It is
notable that this full recovery of function took place even
though the films were continuously exposed to the protein.
Surprisingly, exposure to higher levels of protein after film
formation resulted in films that failed to show meaningful
reductions in surface tension and rarely displayed a surface
tension below 15 mN/m from the start to the end of quasi-static
testing (Fig. 3). In dynamic cycling, surfactant inhibition was all
but gone (median βγ10 8 m/N) but dysfunction showed up again
in the following set of quasi-static cycles (median βγ10 13 m/N).
We allowed one of these latter films to rest overnight after at
which time it was no longer impaired. In contrast, for films
exposed to a lower amount of serum albumin (40 mg/ml) in the
buffer after film formation signs of inhibition had all but
disappeared by the forth quasi-static cycle (median βγ10 8 m/N).
In summary, exposure to albumin and fibrinogen had no lasting
effect on function under the conditions tested. An effect, when
present, was only observed in quasi-static cycling but not in
dynamic cycles. Interestingly, 80 mg/ml albumin had only
limited effect when present at the time of film formation and the
Fig. 2. Area–surface tension isotherms of BLES films exposed to plasma proteins. The isotherms were acquired during film compression. The films were adsorbed to
the air–water interface on unadulterated buffer (upper row) or buffer already containing either albumin (80 mg/ml, middle row) or fibrinogen (3 mg/ml, lower row). For
the first, control, condition 14 tests were carried out but only eight representative cases are shown for clarity and for the two experimental conditions, three or four
individual tests were carried out, indicated by different shades of grey. Note that under these two conditions, all films showed inhibition in the first compression, but
regained full function thereafter.
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with BLES films after film formation if PEG was not added
after the protein. However, even this latter inhibition disap-
peared over time and area cycling.In contrast, 20% cholesterol in surfactant abrogated function
with no recovery (Fig. 4). γ stayed above 15 mN/m throughout
testing. Even a waiting period of 12 h did not lead to recovery of
function of BLES containing 20% cholesterol (Table 1).
Fig. 3. Area–surface tension isotherms of BLES films exposed to albumin (80 mg/ml). Unlike in Fig. 2, the films were adsorbed to clean buffer–air interface first and
the albumin injected afterward. Four individual tests were carried out, indicated by different shades of grey. Under this condition, all films showed severe inhibition
during the course of four quasi-static cycles, but were functional upon dynamic compressions. These films regained full function upon later series of quasi-static
compressions (not shown).
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bition brought about by 80 mg/ml albumin after film formation
could be reversed by the addition of PEG to the buffer. PEG has
been shown to be effective in reversing surfactant inhibition
by proteins (e.g. [17] and references therein). This observation
was explained by the action of PEG to drive surfactant to the
air–water interface by a mechanism called depletion attraction
[33–38]. PEG was thought to specifically counter surfactant
inhibition by competitive adsorption by driving the protein off
the interface and allowing surfactant to adsorb. As expected,
PEG had no effect on cholesterol inhibited surfactant (Table 1).
However, inhibition by 80 mg/ml albumin on previously
formed surfactant films was effectively reversed by adding PEG
even with our current experimental protocol. This was
surprising as the surfactant film resided at the interface priorFig. 4. Area–surface tension isotherms of BLES films containing 20% w/w cholester
Under this condition, all films showed severe inhibition during the course of all qu
regained upon later series of compression–expansion cycles (not shown).to both, exposure to albumin and exposure to PEG. Hence, the
inhibition is not likely to have been by competitive adsorption
in the first place and PEG improved surfactant function in an as
yet unknown way.
3.3. Cryo-electron microscopy
Current results on surfactant inhibition by serum proteins
differ from results reported earlier on that subject in that our
results were not consistent with surfactant inhibition by
competitive adsorption. The one difference in experimental
procedures that might best account for these divergent results
may be the current use of highly concentrated surfactant over
the more dilute suspensions used in the earlier studies. We
therefore studied the influence of concentration on the structuresol. Three individual tests were carried out, indicated by different shades of grey.
asi-static and dynamic compression–expansion cycles. Function was also not
Fig. 5. (left) Cryo-electron micrographs of an aqueous suspension of BLES of 27 mg/ml such as used in the current study, BLES at 5 mg/ml (top right) and BLES at
5 mg/ml plus PEG (bottom right). At high concentration or at low concentration in the presence of PEG, BLES forms dense aggregates of vesicular structures. At low
concentration, BLES forms unilamellar vesicles. For each sample, 5 μl of the suspension was put down onto a bare electron microscopy grid, excess of the suspension
removed by filter paper and the grid injected into liquid ethane. Grids were transferred onto a cryo-holder and imaged in a Tecnai F-20 (FEI) at −100 °C.
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scopy of unstained aqueous suspensions (Fig. 5). At high con-
centration (27 mg/ml) such as used for the CBS studies, BLES
formed dense aggregates of vesicular structures (Fig. 5, left).
Large vesicles were packed with smaller vesicles or other
spherical lipid particles. At a lower concentration (5 mg/ml),
BLES formed unilamellar vesicles (Fig. 5, top right). This or a
lower concentration reflects the condition used in earlier studies
of surfactant inhibition by serum proteins. Adding PEG to 5 mg/
ml of surfactant lead to condensed surfactant aggregates in the
buffer (Fig. 5, bottom right), similar to those observed with
27 mg/ml of surfactant.
4. Discussion
The current findings indicate that under the experimental
conditions chosen here, surfactant inhibition is likely caused by
a dysfunctional film rather than by inhibition via competitive
adsorption of plasma proteins to the air–lung interface. This is
in contrast to earlier studies that demonstrated competition for
the interface by serum proteins such as used in the current study
[14–17]. The following sections will first address the experi-
mental differences between the current and the earlier studies
that could account for this discrepancy. We will then make the
argument why studying surfactant inhibition with highly con-
centrated surfactant rather than dilute surfactant solutions may
better approximate the conditions in the alveolar hypophase and
produce results that could be more immediately relevant to the
diseased lung.According to the inhibition via competitive adsorption
model, serum proteins form a film at the air–water interface.
The layer of serum proteins prevents, or greatly delays, sur-
factant adsorption by repelling surfactant aggregates approach-
ing the interface from the buffer because of its hydration shell as
well as through electrical double layer repulsion [39,40]. In
agreement with this proposed mechanism of inhibition, the
addition of polymers such as polyethylene glycol (PEG) or
hyaluronic acid to the buffer reversed this type of surfactant
inactivation in these earlier studies. The polymers cause sur-
factant to flocculate, but also drive it to the interface by a
mechanism termed depletion attraction [33–38].
In contrast, in the current study film formation was only
minimally delayed by the presence of a film of proteins. Despite
an initially slower drop in surface tension, the total time
required to reach the equilibrium surface tension of 23.5 mN/m
was not increased by plasma proteins in the buffer. In testing
after film formation only limited inhibition by protein was
observed in the first quasi-static cycle when present at the time
of film formation. A high concentration of protein introduced
after film formation produced significant and persistent
inhibition but if PEG was added after the protein or a lower
concentration of protein was used then the observed inhibition
was modest and transient like that seen with protein present at
the interface at the time of film formation. Hence, while there
clearly was an effect of proteins at the interface in our experi-
ments, the effect was transient and so any protein film at the
interfaces seems to have been efficiently replaced by a film of
surfactant.
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tion by competitive adsorption and the current study is best
explained by difference in the concentration of the surfactant
applied; 27 mg/ml for the current study as compared to b2 mg/
ml for most of the earlier studies [14–17] and is consistent with
the findings by Holm et al. [18], where serum albumin
abolished surfactant function at a surfactant concentration of
1 mg/ml but had no effect at only three times this concentration.
The results by Holm and our current findings also show that
surfactant inhibition by competitive adsorption is not linearly
dependent on surfactant concentration and, hence, not merely
subject to mass action. Rather, it appears to be related to the
critical concentration, above which surfactant condenses from a
dispersed suspension of unilamellar vesicles into extended
mesostructures, depending on surfactant and buffer composi-
tion. Such transition has been studied experimentally and
theoretically for lipids [41] and is evident for BLES in the
electron micrographs shown in Fig. 5. According to this view,
surfactant will be susceptible to inhibition by competitive
adsorption if in the dispersed form and not be affected by
competing serum proteins if present in condensed form. BLES
forms unilamellar vesicles (Fig. 5, top right) at 5 mg/ml and
dense aggregates at 27 mg/ml (Fig. 5 left). Diffusion of the
vesicles to the interface and insertion into the interface are slow
even in the absence of plasma proteins (e.g. [7]) and so films
form over a time period measured in minutes. Under these
conditions, the vesicles are apparently unable to effectively
overcome a barrier posed by a film of protein. In contrast film
formation from dense aggregates is effective even in the
presence of a protein film at the interface. Once an aggregate
has come into contact with the interface, it might spread over the
interface, unaffected by the energy barrier encountered by
vesicles. Because each densely packed particle delivers a much
larger amount of surfactant to the interface than its unilamellar
vesicular counterpart, film formation will be accordingly faster.
Interestingly, BLES also forms dense aggregates at low
concentration when in the presence of PEG. This would suggest
that the earlier described effect of PEG in overcoming surfactant
inhibition by serum proteins may not only have been the ef-
fect of driving the (dilute) surfactant to the interface [14–17],
[33–38] but also due to its effect on flocculating the surfactant
and turning it into this physical form which spreads to an air–
water interface so much more effectively.
When evaluating the validity of the current over earlier
findings for explaining surfactant dysfunction in ARDS, one
needs to assess, which of the surfactant concentrations, 27 mg/
ml chosen here or the more typical concentrations of b5 mg/ml
better approximate the alveolar hypophase in the diseased lungs.
The concentration of surfactant has not been directly measured
to date, neither in the healthy nor the diseased lung. The best
available estimate of the alveolar hypophase surfactant con-
centration to our knowledge is that of Clements et al. [42] which
they roughly calculate to be 120 mg/ml phospholipids. These
authors later, referring to the work of Bray, note that their
estimate likely is a conservative one [34,43]. Bray [44] proposed
that local concentrations of surfactant at the interface could be
enhanced by hyaluronic acid or other organizing factor in thesurfactant hypophase. Another line of evidence indicating that
the surfactant hypophase is an organized “structure”with locally
enhanced concentration is that found in EM studies of the lung.
None of these studies present any evidence for the existence of a
uniform suspension of unilamellar vesicles of surfactant, capped
at the air–fluid interface by a phospholipid monolayer. Rather
from the earliest studies [45] the surfactant hypophase is seen as
containing consistent highly organized osmophilic structures
including lamellar bodies, tubular myelin, and a multilamellar
superficial layer. Several authors have also noted a tight
association between tubular myelin and the superficial lamellar
structures [45]. It should be remembered that the osmium used to
produce the contrast in these images is specifically localized to
phospholipids the most abundant constituent of surfactant and so
reveal the structured non-homogeneous distribution of surfac-
tant in the hypophase. Subsequent investigations have largely
ruled out artifact as a significant factor in these studies and
revealed more subtle details of this organization [5,7,46,47].
This leads us to conclude that the complex organization in the
lung is functionally important for the surface tension altering
effects of pulmonary surfactant and that the “self organization”
occurring with more concentrated material would be qualita-
tively different from that formed in more dilute surfactant
solutions. In a recent comparative study of BLES and other
hydrophobic animal extract surfactants with natural surfactant in
vitro showed comparable surface activities in a CBS but also
quite similar structures (with the exception of the lack of tubular
myelin for the animal extract surfactants) at the air–water inter-
face as obtained by electron microscopy [8]. This is irrespective
of the deficiency in the water soluble surfactant associated
proteins A and D (SP-A, SP-D) for the hydrophobic extract
surfactants.
However, SP-A and SP-D might play an important role in the
injured lung, when surfactant in the alveolar fluid becomes
diluted and dispersed by edema. SP-D and SP-A both have been
shown to keep surfactant from dispersing in a more dilute
suspension [48] and prevent it from becoming more susceptible
to inhibition by competitive adsorption. The naturally occurring
hyaluronic acid in the alveolar fluid is another substance that
keeps surfactant condensed and close to the air–alveolar inter-
face [44]. Together, the above in vitro and in vivo findings lead
us to conclude that the approach chosen in the current study
over earlier experiments is more likely to reflect the situation in
the lung and the choice of BLES at 27 mg/ml is appropriate
when assessing surfactant inhibition. As a consequence, com-
petitive adsorption is not likely occurring in the lung as the
initial inhibitory mechanism. However, we would not rule out
the possibility that when its constituents become degraded by
mechanisms discussed below and other disease related-mech-
anisms, surfactant may no longer maintain a condensed struc-
ture and may eventually become susceptible to inhibition by
competitive adsorption as well.
There are more reasons for surfactant inhibition by
competitive adsorption not to occur as the primary inhibition
mechanism. Firstly, serum albumin is in the alveolar space even
in the healthy lung at relatively high concentrations where it
does no damage to the surfactant system. Ishizaka et al. reported
442 L. Gunasekara et al. / Biochimica et Biophysica Acta 1778 (2008) 433–4448 mg/ml albumin in the alveolar fluid of a lung in healthy
individuals [49]. This is above a buffer concentration beyond
which the equilibrium surface tension of serum albumin
becomes largely independent of the buffer concentration and
competitive adsorption should have reached its maximum level
(∼0.1 mg/ml; [50]). Furthermore, for competitive adsorption to
occur, a protein film would need to be in place before surfactant
had time to form a film on its own and lower the surface tension
to below the equilibrium surface tension value for the respective
protein (∼43 mN/m for albumin and∼37 mN/m for fibrinogen,
according to the current study). At an equilibrium surface
tension of surfactant below 24 mN/m, protein molecules are
unlikely to insert into the interface and displace surfactant. On
the other hand, surfactant with its higher surface activity,
evident from a lower equilibrium surface tension, can drive a
protein film from the interface.
While our findings do not support surfactant inhibition by
competitive adsorption as the primary inhibitory mechanism,
serum proteins still caused functional inhibition of surfactant.
The first quasi-static compression of the surfactant films
revealed elevated compressibility. The interfacial area needed
to be reduced at least by 50% to lower the surface tension from
equilibrium to near zero as compared to about 15% in the
absence of proteins. For all conditions tested, some films
never reached a low surface tension in the presence of proteins
in Q-Stat 1. Remarkably, the inhibition by proteins was most
pronounced when the exposure occurred after the surfactant
films had been formed and a high concentration of surfactant
was used. This inhibition was transient and all cases, except
those where a high concentration of albumin was added after
film formation, showed quick and sustained recovery. The latter
had slower and somewhat transient recovery.
We have no detailed explanation how serum proteins
interfere with surfactant. However, comparison with films
inhibited by cholesterol is illustrative. Film adsorption to the
equilibrium value was not affected by an excess of cholesterol
or exposure to proteins in the buffer but the films could not
withstand a film pressure associated with a surface tension
below equilibrium. This resulted in an extended plateau in the
surface tension–area isotherm for the cholesterol inhibited
films which was greater than the most extreme cases of protein
inhibition. Below equilibrium surface tension, an interfacial
film is metastable by definition (i.e. once matter has left the
film, it can no longer return). It is a unique mechanical property
of a pulmonary surfactant to not collapse under this condition.
This property has been associated with specific film architec-
ture of a monolayer and dispersed multilayer patches [51,52]
and excess cholesterol has been shown to disrupt this structure
[20]. By analogy, serum protein might also interfere with this
film structure. Nag et. al [53] showed that albumin interacts
intimately with the lipids of surfactant causing them to
redistribute into a phase pattern not present in the absence of
the protein.
In dynamic cycling, all protein exposed films achieved
near-zero surface tension even when they showed inhibition
during quasi-static cycling before and after the dynamic cy-
cles. Film collapse is time dependent and films may remainintact under pressure for a short while but collapse over longer
time periods. Dynamic cycling is therefore a less rigorous
stability test and reveals the impairment only for the most
severely inhibited surfactants. To judge whether surfactant
maintains near-zero surface tension in areas of the lung that are
not undergoing area change during tidal breathing, quasi-static
cycling or other near static surfactant evaluations are therefore
required.
A surprising finding of this study was that films allowed to
form in absence of serum protein became (transiently) inhibited
after exposure to proteins while films formed in the presence of
serum protein were already functional after a single compres-
sion–expansion cycle. This effect was most pronounced for
80 mg/ml albumin, which resulted in minimal inhibition when
present during film formation but was most inhibitory if added
to the aqueous phase after film formation and then showed
recovery over with successive cycles with proteins present.
Hence, pulmonary surfactant appears to possess a mechanism
that makes it tolerant to exposure to serum proteins.
5. Conclusion
The current study contradicts surfactant inhibition by
competitive adsorption by serum albumin and fibrinogen as
the primary mechanism of surfactant inhibition. It appears
unlikely to us that this mechanism would hold true for any other
plasma or inflammatory protein present in the injured lung as
long as the surfactant itself is undamaged. Instead, we found
that inhibition by proteins appears to occur via interference with
the surfactant film itself. Inhibition was transient for the two
proteins tested and the surfactant films became insensitive to
their continued presence. This is likely important for normal
lung function where at least serum albumin is always present in
the alveolar space and is just elevated in ARDS. There is good
evidence that other serum or inflammatory proteins may cause
more lasting surfactant impairment than albumin and fibrinogen
(e.g. [54]). We expect this to occur at least initially via inter-
ference with the film structure and not through competitive
adsorption. However, we note that surfactant inhibition by
competitive adsorption might occur, once the surfactant has
become deficient in its composition and become unable to
maintain a condensed structure.
Identification of the relevant mechanism of surfactant im-
pairment in ARDS is important for devising new strategies to
counter the inhibition and overcome the current lack of success
with exogenous surfactant treatment. The current study does not
support the rationale for a treatment that primarily addresses
competitive adsorption by introducing hydrophilic polymers
such as PEG into the alveolar space as proposed (e.g. [17,40]).
Our results for cholesterol inhibition show that addition of PEG
has no positive effect on surfactant inhibited by cholesterol. An
effective treatment, may have to specifically counter the effect
of cholesterol and other small hydrophobic molecules and also
target other mechanisms, including oxidation of surfactant
through the reactive oxygen species present in the injured lung
[21–24,55] and interference with serum and inflammatory
proteins.
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